Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
2025-11-24: Biogen and Dayra partner on oral macrocyclic peptides with $50 million upfront
Program / service
Target / indication
Representative stage
Evidence & scope
Biogen–Dayra oral macrocycles in immunology
Not disclosed · Not disclosed
未披露
Quantitative human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Biogen and Dayra announced a research collaboration to discover and optimize oral macrocyclic peptides for immunological targets. Dayra receives $50 million upfront and may receive candidate-acquisition payments and development milestones per program. Biogen would lead subsequent development, manufacturing, and potential commercialization. The agreement concerns early discovery rather than established clinical efficacy.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
